Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07072143

An International Study on Pediatric Patients With Rare Tumors.

The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Paraganglioma/ Phaeochromocytoma Adenoma Adrenal Cortex Diseases Adrenal Cortex Neoplasms Adrenal Gland Diseases Adrenal Gland Neoplasms Adrenocortical Tumor Appendiceal Cancers Carcinoma Cranial Nerve Diseases Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Esthesioneuroblastoma, Olfactory Gastrointestinal Diseases Gastrointestinal Neoplasms Gastrointestinal Stromal Tumor (GIST) Gastrointestinal Stromal Tumors Head and Neck Neoplasms Hemic and Lymphatic Diseases Lymphatic Diseases Melanoma Melanoma and Other Malignant Neoplasms of Skin Mesothelioma NUT Carcinoma Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma (NPC) Nasopharyngeal Diseases Nasopharyngeal Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Connective Tissue Neoplasms, Connective and Soft Tissue Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Mesothelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Nervous System Diseases Neuroblastoma Neuroectodermal Tumors Neuroectodermal Tumors, Primitive Neuroectodermal Tumors, Primitive, Peripheral Neuroendocrine Tumors Nevi and Melanomas Olfactory Nerve Diseases Otorhinolaryngologic Diseases Otorhinolaryngologic Neoplasms Pancreatic Diseases Pancreatic Neoplasms Pancreatic Tumors Pharyngeal Diseases Pharyngeal Neoplasms Pleuropulmonary Blastoma Salivary Gland Tumors Skin Diseases Skin Neoplasms Skin and Connective Tissue Diseases Stomatognathic Diseases Thoracic Neoplasms Thymic Tumors Thymus Neoplasms Thyroid Carcinoma Thyroid Diseases Thyroid Neoplasms

Age range

0 year–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Pediatric Oncology Unit, University Hospital Padova [AOUP Azienda Ospedale Università Padova]

Padova, Italy, 35127

Location status: Recruiting

Location contact

Calogero Virgone, Pediatric Surgeon

SUB_INVESTIGATOR

Gianni Bisogno, Medical Doctor

CONTACT

[email protected]

0039 0498211481

Gianni Bisogno, Medical Doctor

PRINCIPAL_INVESTIGATOR

Martina Bonel, Study Coordinator

CONTACT

[email protected]

0039 049 8214413

About this study

There are some very rare tumors (with an annual incidence of less than two per million children) that can affect children and adolescents. These neoplasms include a wide variety of cancers; some are rare at any age, while others are typical of adults but very rare in children. Due to their rarity, studies have so far been scarce, often lacking univocal diagnostic criteria, and more information is needed to improve treatment outcomes.

The aim of this study is to collect epidemiological, clinical, biological, radiological and treatment data on children and adolescents with rare cancers in order to improve our understanding of these tumors and how their clinical and biological characteristics affect treatment outcomes.

Due to the rarity of these malignancies, international collaboration is necessary to collect sufficient data on each tumour type.

While the investigators are not proposing specific treatments, the data collected will inform recommendations for the diagnosis and treatment of patients.

The PARTNER Study is an observational, prospective study. It is sponsored by Padua University Hospital AOUP (Italy), and all European centres collaborating with the EXPeRT group have been invited to participate. It is a non-profit study, meaning it has no commercial purpose, only the aim of improving knowledge and treatment for children with rare cancers. PARTNER activities are supported in different countries by national funds, as well as by the European Commission through the European Reference Network for Paediatric Oncology (ERN PaedCan). Please visit https://paedcan.ern-net.eu/ for more information.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children and adolescents (age 0-18 years) with a primary or relapsed Very Rare Tumor diagnosed and/or treated in a participating country/center.
  • Written informed consent from the patient and/or the parent/legal guardian

Exclusion criteria

  • Absence of Written informed consent from the patient and/or the parent/legal guardian

Treatment and study plan

Primary outcomes

  1. Epidemiology

    Time frame: through study completion, an average of 1 year

    Evaluate the number of patients (aged 0-18 years) with different Very Rare Tumors in the different countries: observed cases will be compared with expected cases.

  2. Use of International Recommendations

    Time frame: through study completion, an average of 1 year

    The study aims to measure the number of patients treated for different neoplasms in different countries, and the proportion of those treated in accordance with the International Recommendations.

  3. Survival of children and adolescents (0-18 years) affected by Very Rare Tumors

    Time frame: through study completion, an average of 1 year

    The study will correlate the clinical characteristics of the tumor (size, site, extension) with the treatment, the risk of recurrence and survival.

Study contacts

Contact information is provided by the study sponsor or research team.

Gianni Bisogno, MD

CONTACT

[email protected]

0039 0498211481

Martina Bonel, CRC

CONTACT

[email protected]

0039 04908211481

Sponsors and collaborators

Lead sponsor

Azienda Ospedaliera di Padova

Other

Collaborators

  • Bucharest Emergency Hospital
  • Centre Hospitalier Universitaire de La Réunion, FRANCE
  • Centro Hospitalar do Porto
  • Children's Hospital Zagreb
  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
  • Gdansk Medical University (Poland)
  • Göteborg University
  • Hellenic Oncology Research Group
  • Institute for Oncology and Radiology Serbia, Belgrade
  • Kaplan Medical Center, Rehovot, Israel
  • Klinikum Dortmund
  • St. Anna Children's Hospital, Vienna
  • University Children's Hospital Tuebingen
  • University Hospital Bratislava
  • University Hospital, Paris
  • University Medical Centre Ljubljana
  • University of Bilbao
  • University of Skopje
  • Vilnius University Hospital Santaros Klinikos

Registry information

Official study title

The PARTNER Study - An International Prospective Observational Study on Pediatric Patients With Very Rare Tumors.

Acronym: PARTNER

Important dates

Study start
2025
Primary completion
2049
Study completion
2049
First posted
Jul 18, 2025
Registry last updated
Jul 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.